105
105 years of development
119
Vaccine coverage over 119 countries and regions
15
15 innovative drugs under R&D
3
3 production workshops with a hundred-of-million production scale of COVID-19 Inactivated Vaccine (Vero Cell)
News Recommendation
Communication Fosters Consensus, Lea
2025-10-30
Secretary Li Xinguo, Financial Director Zhang Hui, Deputy General Manager Yang Ming, and managers from relevant departments. During the event, delegates visited the A Centennial Exhibition Hall of China Biological Products ...
View More+Breaking News! BIBP’s Polio Vaccine
2025-08-01
On July 18, the 5-dose Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains (sIPV), independently developed by the Beijing Institute of Biological Products Co., Ltd. (BIBP), part of the China National Biotec Group Company Limit...
View More+Africa CDC Delegation Visits BIBP
2024-12-31
On December 17, a delegation from the Africa CDC, led by Director Jean Kaseya and accompanied by Wang Lili, Associate Researcher at the Global Public Health Center of the Chinese Center for Disease Control and Prevention, along with a g...
View More+About Company
Beijing Institute of Biological Products Co., Ltd. (BIBP), a subsidiary of China National Biotec Group Company Limited (CNBG), China National Pharmaceutical Group Co., Ltd. (Sinopharm), is engaged in the research, production and marketing of vaccines, diagnostic preparations and other biological products, with a registered capital of CNY 2.3 billions. The history of BIBP can be traced back to 1919 when National Epidemic Prevention Bureau was established by the Beiyang Government, representing the cradle of biological products for The People's Republic of China.
Achievements More+Scientific Research and Innovation
